FDA Accepts Critical Therapeutics Asthma Drug for Review
Posted on: Wednesday, 18 October 2006, 12:01 CDT
The FDA has accepted Critical Therapeutics new drug application for zileuton for the treatment of chronic asthma.
The company submitted the application in late July and, pending regulatory approval, expects to launch zileuton CR in the second half of 2007.
The new drug application includes results from two previously completed phase III trials that evaluated the safety and efficacy of zileuton in asthma patients. It also includes the results from two comparative bioavailability studies intended to bridge Critical Therapeutics' formulation to the formulation used in the phase III trials.
Critical Therapeutics currently markets its asthma drug Zyflo, the immediate-release formulation of zileuton, in the US. Zyflo is the only 5-lipoxygenase inhibitor approved for marketing by the FDA.
"We expect zileuton to build on the market penetration of Zyflo and to enhance compliance by allowing patients to follow a more convenient and manageable twice daily dosing schedule," said Critical Therapeutics' president Frank Thomas.
Source: Datamonitor
Related Articles
- Dey L.P. And Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
- CyDex Licenses Captisol(R) to Critical Therapeutics for Injectable Formulation of Zileuton
- Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma
- Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA
- Critical Therapeutics Announces Research on ZYFLO(R) Presented at 2006 AAAAI Annual Meeting
- Critical Therapeutics Announces FDA Approval of ZYFLO(R) for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms
- Two Studies Support Efficacy of Critical Therapeutics' ZYFLO in Moderate to Severe Asthma Patients; Data Presented at the American Thoracic Society's 2005 International Conference
- Critical Therapeutics Submits Supplemental New Drug Application to FDA for ZYFLO
- Critical Therapeutics Initiates Open-Label Study of ZYFLO; Study Provides Certain Patients Access to ZYFLO Prior to Commercial Availability
 |
 |
User Comments (0)
RSS Feeds